StreetAlpha.app
Home › Stocks › CYTK

Cytokinetics Inc (CYTK)

Healthcare
$50.78
▼ −1.32%
LAST CLOSE · NOV 20

Cytokinetics develops medicines that act on muscle function, starting with MYQORZO for obstructive hypertrophic cardiomyopathy, a serious heart disease. It last closed at $50.78 on Nov 20, down 1.32% on the day. The next earnings report for CYTK is expected around Tue, Feb 23, 2027, after the close. For the quarter ended Sep 2026, CYTK reported EPS of -$1.37 on revenue of $47.6M, with revenue up 2356.5% from a year ago. Over its last 8 reports the stock moved an average of 5.3% the session after earnings. Over the last 12 months CYTK insiders bought $0 of stock on the open market and sold $52.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is CYTK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CYTK.

Key Stats

Last 12 months
Results
Revenue
$113.3M
+29.9% vs a year ago
Net income
−$777.9M
−686.6% margin
EPS (diluted)
−$6.02
Free cash flow
−$588.6M
−519.5% margin
Valuation
Market cap
$7.1B
139.3M shares
P/E
–
No P/E while losing money
Price to sales
62.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$203.4M
At Sep 30
Debt
$418.7M
At Sep 30
Shareholder equity
−$321.2M
Shares outstanding
139.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $70.4M$70.4MFY2021FY2022: $94.6M$94.6MFY2022FY2023: $7.5M$7.5MFY2023FY2024: $18.5M$18.5MFY2024FY2025: $88.0M$88.0MFY2025

From CYTK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 23
Estimated date · After the close
Reported EPS
-$1.37
Quarter ended Sep 2026
Year ago EPS
-$2.55
Same quarter last year
Revenue
$47.6M
+2356.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.26Dec '24Mar 2025: -$1.36Mar '25Jun 2025: -$1.12Jun '25Sep 2025: -$2.55Sep '25Dec 2025: -$1.50Dec '25Mar 2026: -$1.67Mar '26Jun 2026: -$1.50Jun '26Sep 2026: -$1.37Sep '26Latest -$1.37
Revenue by quarter
Dec 2024: $16.9MDec '24Mar 2025: $1.6MMar '25Jun 2025: $66.8MJun '25Sep 2025: $1.9MSep '25Dec 2025: $17.8MDec '25Mar 2026: $19.4MMar '26Jun 2026: $28.6MJun '26Sep 2026: $47.6MSep '26Latest $47.6M
How CYTK moved after its last 8 reports
Average move the session after a report ±5.3%
Nov 4, 2026After the close−12.7%
Aug 6, 2026After the close−5.7%
May 5, 2026After the close−2.9%
Feb 24, 2026After the close−10.3%
Nov 5, 2025After the close+1.9%
Aug 7, 2025After the close−3.2%
May 6, 2025After the close−2.7%
Feb 27, 2025After the close−3.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CYTKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on CYTK: 0 upgrades, 0 downgrades, 0 initiations · Targets mentioned $100.00
JPMorgan Chase & CoNew target
Nov 21 $100.00
JPMorgan Chase & CoTarget cut
Nov 20  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on CYTK
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CYTK

Technical Analysis

CYTK · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 13% below its 20 day and 22% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $50.32, and the nearest resistance the Pivot at $51.61.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 5.2%/day
Key levels
$88.3152 week high+73.9%
$70.11100 day average+38.1%
$69.49200 day average+36.8%
$61.8950 day average+21.9%
$59.08Swing high (Nov 11)+16.3%
$57.3820 day average+13.0%
$52.62Pivot R1+3.6%
$51.61Pivot+1.6%
$50.78Last close
$50.3252 week low−0.9%
$49.77Pivot S1−2.0%
Indicators
RSI (14)29.60Oversold below 30Oversold
MACD-3.24Below its signal lineBearish
Stochastic4.4Near the bottom of its rangeOversold
ADX (14)29.9Trending down
Williams %R-96.9Oversold below −80, overbought above −20Oversold
CCI (20)-105.2Oversold below −100, overbought above 100Oversold
Rate of change−5.4%Change over 10 sessionsBearish
ATR (14)$2.62Typical daily range, 5.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CYTK

What happened before

See how CYTK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CYTK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CYTK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CYTKHow many large options trades hit CYTK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

CYTK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲269 buying vs 200 selling
  • ▲Held by funds +13.3 pts
  • ▼Funds holding -13
  • ▼Superinvestors: 1 added, 2 cut
  • ▲Put/call 0.08 to 0.06
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding474487−2.7%
In funds' top 101315−13.3%
Held by funds128.6%115.3%+13.3 pts
New / increased62 / 20791 / 237−18.0%
Reduced / sold out127 / 73102 / 50+31.6%
Put/call ratio0.060.08−18.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CYTK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CYTK Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$52.9M78 sales · 11 insiders
90% of the selling was under pre-arranged trading plans.
2025-12 sold $7.8M2026-01 sold $1.0M2026-02 sold $984K2026-03 sold $7.1M2026-04 sold $3.4M2026-05 sold $7.3M2026-06 sold $6.2M2026-07 sold $4.9M2026-08 sold $2.1M2026-09 sold $8.8M2026-10 sold $910K2026-11 sold $2.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Jeffrey HessekielChief Legal & Admin OfficerSale15,106$52.62$795K
Nov 17Fady Ibraham MalikEVP Research & DevelopmentSale plan3,500$51.78$181K
Nov 16Robert I BlumPresident & CEOSale plan7,500$53.53$401K
Nov 9B Lynne ParshallDirectorSale plan5,000$54.73$274K
Nov 3Fady Ibraham MalikEVP Research & DevelopmentSale plan3,500$62.93$220K
Nov 2Robert I BlumPresident & CEOSale plan7,500$62.81$471K
Every insider buy and sale for CYTK over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CYTK insider trades →

From SEC Form 4 filings by CYTK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CYTK is in one of them and how their past CYTK trades turned out.

CYTK in the AI portfolios
Loading…

CYTK News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CYTK in an article yet. Here's the latest on the wider market.

CYTK in the news

CYTK Congress Trades

All congress trades →
Trades, 12 months
2
Buys
2
100%
Sells
0
0%
People
1
Last filed Oct 12
Who traded CYTK · since 2025
Latest 5 filings
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$1K – $15KTraded Jun 30, 2026Filed Jul 2, 2026
$1K – $15KTraded Oct 9, 2025Filed Nov 18, 2025
$1K – $15KTraded Jun 17, 2025Filed Aug 13, 2025
$1K – $15KTraded Jun 11, 2025Filed Aug 13, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KSep 29, 2026Oct 12, 202613 d
Gilbert CisnerosD · CABuy$1K – $15KJun 30, 2026Jul 2, 20262 d
Gilbert CisnerosD · CABuy$1K – $15KOct 9, 2025Nov 18, 202540 d
Lisa McClainR · MISell$1K – $15KJun 17, 2025Aug 13, 202557 d
Lisa McClainR · MIBuy$1K – $15KJun 11, 2025Aug 13, 202563 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Cytokinetics

Cytokinetics is a biopharmaceutical company based in South San Francisco, California, that develops medicines aimed at muscle function. Its first approved product is MYQORZO, a tablet for adults with obstructive hypertrophic cardiomyopathy, a serious heart disease. The company sells its medicines to patients and to prescribing cardiologists, and it is working on other drug candidates for heart and neuromuscular diseases.

Headquarters
South San Francisco, CA
Founded
1997